Q-omics provides the consensus-scored TUBA4B profile across patient tissues and cancer cell-line models. TUBA4B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TUBA4B is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, TUBA4B RNA expression shows 12,534 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, KICH, and TGCT as cancer lineages where TUBA4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBA4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBA4B survival associations across molecular data types. TUBA4B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBA4B RNA expression–survival associations across cancer types. High TUBA4B expression shows unfavorable associations in MESO, LIHC and ACC, but favorable associations in BRCA, READ and ESCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TUBA4B RNA expression.
This table summarizes TUBA4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TUBA4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBA4B shows lower tumor expression in KICH, LUSC, LUAD and KIRP and higher tumor expression in COAD and LIHC. The KICH box plot shows higher TUBA4B RNA expression in normal versus tumor tissue (log2 FC = −1.370, t-test p < 0.001).
This table shows molecular features associated with TUBA4B in patient tissues and cancer cell lines. In patient samples, TUBA4B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBA4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
